Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Shital Jibhe Article rating: 5.0

Overall volumes in futures & options currently stand at 1.63 crore contracts with a turnover of Rs. 10,11,506.05 crore.

Index trend and stocks in action February 21, 2019
Index trend and stocks in action February 21, 2019

Index trend and stocks in action February 21, 2019

Karan Dsij Article rating: 5.0

On the downside, the level 10,680 is likely to act as an immediate resistance as the 100-day moving average is placed at this level. Stocks in news: Shriram Transport Finance, Dr Reddy’s Laboratories, Grasim Industries, BPCL, REC, Jubilant Life Sciences, Tata Steel and Yes Bank.

Flat to negative start likely amid mixed cues from Asian peers
Flat to negative start likely amid mixed cues from Asian peers

Flat to negative start likely amid mixed cues from Asian peers

Karan Dsij Article rating: 5.0

The outlook for the day flat to negative start as the SGX Nifty at the time of writing is seen trading down by 30 points at 10,737. Also, the cues from the Asian peers are not clear, hence tentativeness may persist, but we cannot rule out bargain hunting at lower levels. Hence, the level of 10,680 would be a crucial support level to watch out for the index. Meanwhile, in a big boost to the public sector banks, the government approved the recapitalisation of Rs 48,239 crore for 12 public sector banks. 

Overnight Digest: Stocks to look out on February 21
Overnight Digest: Stocks to look out on February 21

Overnight Digest: Stocks to look out on February 21

Shohini Nath Article rating: 5.0

The stocks that are likely to witness significant movement on the bourses on February 21 are Cyient, NHPC, Jindal Worldwide, TRF and Shakti Pumps

HG Infra surges; bags L1 for NHAI project
HG Infra surges; bags L1 for NHAI project

HG Infra surges; bags L1 for NHAI project

Apurva Joshi Article rating: 4.6

HG Infra has been declared as L1 bidder by National Highways Authority of India (NHAI), New Delhi for new EPC project for construction of 6-lane access.

Alembic Pharma gets USFDA approval for Acetazolamide Capsules
Alembic Pharma gets USFDA approval for Acetazolamide Capsules

Alembic Pharma gets USFDA approval for Acetazolamide Capsules

Apurva Joshi Article rating: 3.7

Alembic Pharmaceuticals has announced that it has received approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acetazolamide Extended-Release Capsules, 500 mg.

Strides Pharma receives USFDA approval for neuro drug
Strides Pharma receives USFDA approval for neuro drug

Strides Pharma receives USFDA approval for neuro drug

Nidhi Jani Article rating: 5.0

Strides Pharma Science, Bengaluru-based pharma company announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has received USFDA approval for Ethosuximide Softgel Capsules.


Andhra Bank plans stake sale in IndiaFirst Life
Andhra Bank plans stake sale in IndiaFirst Life

Andhra Bank plans stake sale in IndiaFirst Life

Dnyanada Kulkarni Article rating: 4.5

Andhra Bank intends to sell its 30 per cent stake in IndiaFirst Life Insurance Company either in part or in full. By doing so, it aspires to raise Rs. 900 crore. One of the candidates who could potentially purchase the stake is the existing investor, Warburg Pincus.

Should you dispose of your real estate investment and buy mutual funds?
Should you dispose of your real estate investment and buy mutual funds?

Should you dispose of your real estate investment and buy mutual funds?

Henil Shah Article rating: 4.0

Many financial advisers have been asking people to invest in mutual funds rather than real estate due to good returns in the long-term. So, should you dispose of your real estate investment and invest in mutual funds? Let’s find out.

RSS
First26782679268026812683268526862687Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR